



ROLE OF NEUROIMAGING IN UNDERSTANDING SCHIZOPHRENIA

AKRITI SINGH

Student

Dr. Madhu Pandey

(Assistant Professor)

Amity Institute of Behavioral and Allied Sciences

Amity University, Lucknow

Uttar Pradesh, India

Abstract: Schizophrenia is a severe psychiatric disorder characterized by disturbances in perception, cognition, emotional regulation, and behavior. Increasing scientific evidence suggests that structural and functional abnormalities in the brain play a crucial role in the development and manifestation of the disorder. The present study examines the role of neuroimaging techniques in understanding schizophrenia and explores the relationship between neuroimaging findings and clinical symptom severity.

A quantitative, descriptive, and correlational research design was adopted. The study included 17 individuals diagnosed with schizophrenia, comprising 9 males and 8 females. Symptom severity was assessed using the Positive and Negative Syndrome Scale (PANSS), while neuroimaging data were obtained from clinical records including Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), and Functional Magnetic Resonance Imaging (fMRI).

Descriptive statistics were used to summarize the distribution of symptom severity across positive, negative, and general psychopathology domains. The Mann–Whitney U test was applied to examine gender differences, and Spearman's rank correlation was used to analyze relationships among symptom variables.

The findings indicated that both male and female patients demonstrated comparable levels of symptom severity. Although females showed slightly higher mean scores across PANSS domains, these differences were not statistically significant. Correlation analysis revealed strong relationships among symptom domains but no significant association between gender and neuroimaging outcomes.

The study highlights the importance of integrating neuroimaging findings with standardized clinical assessments to improve understanding of schizophrenia.

Keywords: Schizophrenia, Neuroimaging, PANSS, MRI, CT Scan, PET Scan, fMRI, Symptom Severity, Mann–Whitney U Test, Spearman Correlation.

INTRODUCTION

Schizophrenia is a chronic and disabling psychiatric disorder that affects approximately one percent of the global population. The disorder is characterized by disturbances in perception, thinking, emotion, and behaviour. Individuals with schizophrenia typically present with three major symptom categories: positive symptoms such as hallucinations and delusions, negative symptoms such as social withdrawal and reduced emotional expression, and cognitive impairments including difficulties in attention, memory, and executive functioning.

Historically, schizophrenia was primarily understood through clinical observation and symptom-based classification systems. However, these approaches provided limited insight into the biological mechanisms underlying the disorder. Over the past few decades, psychiatric research has increasingly focused on integrating neuroscience with clinical psychiatry. This shift has led to the development of biologically informed models that emphasize the role of brain abnormalities in schizophrenia.

One of the most influential frameworks in schizophrenia research is the **neurodevelopmental hypothesis**, proposed by Weinberger (1987). According to this model, schizophrenia results from abnormal brain development occurring early in life, which remains clinically silent until adolescence or early adulthood when major brain maturation processes take place. This perspective has stimulated extensive research investigating structural and functional brain abnormalities in individuals with schizophrenia.

Neuroimaging techniques have played a significant role in advancing knowledge about the neural mechanisms associated with schizophrenia. These techniques allow researchers to examine brain structure, activity, connectivity, and neurochemical processes in living individuals. Common neuroimaging methods include Magnetic Resonance Imaging (MRI), Functional Magnetic Resonance Imaging (fMRI), Computed Tomography (CT), and Positron Emission Tomography (PET).

Structural imaging studies have consistently demonstrated reductions in grey matter volume and enlargement of the brain ventricles in individuals with schizophrenia. These abnormalities are frequently observed in the prefrontal cortex, temporal lobes, hippocampus, and anterior cingulate cortex. Such findings suggest that schizophrenia is associated with widespread alterations in brain morphology.

Functional neuroimaging studies have also revealed abnormalities in brain activity during cognitive tasks. For example, research has shown reduced activation in the dorsolateral prefrontal cortex during working memory tasks. Similarly, alterations in limbic system activity have been associated with emotional processing deficits and social cognition impairments.

In addition to structural and functional abnormalities, neuroimaging research has highlighted disruptions in neural connectivity. Modern theories such as the **dysconnectivity hypothesis** propose that schizophrenia results from impaired communication between distributed brain networks rather than damage to specific brain regions.

Overall, neuroimaging has become an essential tool for linking clinical symptoms with underlying brain mechanisms. Understanding how neuroimaging findings relate to symptom severity may help improve diagnosis, early detection, and treatment planning in schizophrenia.

AIM OF THE STUDY

The aim of the present study is to examine the role of neuroimaging techniques in understanding schizophrenia by exploring the relationship between brain imaging findings and the severity of clinical symptoms.

OBJECTIVES OF THE STUDY

1. To assess the severity of positive, negative, and general symptoms in patients with schizophrenia using the PANSS scale.
2. To examine neuroimaging findings among individuals diagnosed with schizophrenia.
3. To compare symptom severity between male and female patients.
4. To evaluate the relationship between neuroimaging findings and clinical symptom severity.
5. To determine the contribution of neuroimaging in understanding schizophrenia.

SIGNIFICANCE OF THE STUDY

Schizophrenia is widely recognized as a complex psychiatric disorder with significant biological foundations. Neuroimaging techniques provide valuable insights into the structural and functional abnormalities associated with the disorder. By examining the relationship between neuroimaging findings and symptom severity, researchers can gain a deeper understanding of the biological mechanisms underlying schizophrenia.

This study contributes to the growing body of literature supporting the neurobiological basis of schizophrenia. It also emphasizes the importance of integrating neuroimaging findings with clinical assessment tools such as the PANSS scale. Such integration may enhance diagnostic accuracy and improve treatment planning.

REVIEW OF LITERATURE

Research on schizophrenia has undergone significant transformation over the past few decades. Early studies primarily focused on clinical descriptions of symptoms. However, the integration of neuroscience and psychiatry has led to the development of biologically oriented models of the disorder.

Structural neuroimaging studies have provided strong evidence of anatomical abnormalities in schizophrenia. Research using MRI and CT scans has demonstrated ventricular enlargement and reductions in total brain volume among individuals with schizophrenia. These abnormalities are often observed in the prefrontal cortex and temporal regions.

Studies involving first-degree relatives of individuals with schizophrenia have revealed similar but less pronounced brain abnormalities. These findings suggest that structural brain alterations may represent biological markers associated with genetic vulnerability.

Functional neuroimaging studies have further expanded understanding of schizophrenia by examining brain activity during cognitive tasks. Research has consistently shown dysfunction in the dorsolateral prefrontal cortex, particularly during working memory tasks. Such abnormalities are believed to contribute to cognitive deficits commonly observed in individuals with schizophrenia.

In addition to cognitive dysfunction, neuroimaging studies have identified abnormalities in emotional processing networks. Altered activation of the amygdala and other limbic structures has been linked to difficulties in interpreting emotional expressions and social cues.

Another important area of research concerns the role of dopamine in schizophrenia. The dopamine hypothesis suggests that excessive dopaminergic activity in certain brain regions contributes to the development of psychotic symptoms. PET imaging studies have provided strong evidence of increased dopamine synthesis and release in individuals with schizophrenia.

Recent research has also emphasized the importance of neural connectivity. Network-based approaches using graph theory have demonstrated that schizophrenia is associated with disrupted communication between different brain regions. This supports the dysconnectivity hypothesis, which proposes that schizophrenia results from abnormal integration of neural networks.

Overall, the literature indicates that schizophrenia involves complex interactions among genetic, neurodevelopmental, and environmental factors. Neuroimaging provides a powerful method for studying these interactions and for identifying biological markers associated with the disorder.

METHODOLOGY

Research Design

The study employed a quantitative, descriptive, and correlational research design. The descriptive approach was used to examine symptom severity and neuroimaging findings, while the correlational approach was used to assess relationships between imaging results and clinical symptoms.

Sample

The study sample consisted of **17 patients diagnosed with schizophrenia**.

- Male participants: 9
- Female participants: 8

Participants were selected using **purposive sampling** based on predefined inclusion criteria.

Inclusion Criteria

- Diagnosis of schizophrenia based on standard diagnostic criteria
- Both male and female participants
- Patients who had undergone neuroimaging procedures
- Participants willing to provide informed consent

Exclusion Criteria

- Presence of neurological disorders unrelated to schizophrenia
- Substance-induced psychotic disorders
- Intellectual disability
- Severe medical conditions affecting cognitive functioning

Tools and Instruments

1. **Socio-Demographic Data Sheet**
Used to collect personal and clinical information.
2. **Positive and Negative Syndrome Scale (PANSS)**
A standardized clinical instrument used to measure symptom severity in schizophrenia.
3. **Neuroimaging Reports**
Clinical imaging reports obtained from hospital records including MRI, CT, PET, and fMRI.

Procedure

Permission was obtained from the relevant clinical institution before data collection. Participants who met the inclusion criteria were approached and informed consent was obtained. The PANSS scale was administered to assess symptom severity, and neuroimaging reports were collected from clinical records. All data were coded and entered into SPSS software for analysis.

Statistical Analysis

The following statistical methods were used:

- **Descriptive statistics** (mean, standard deviation, frequency)
- **Mann–Whitney U test** to compare gender differences
- **Spearman’s rank correlation** to examine relationships among variables

The level of significance was set at **0.05**.

RESULTS AND INTERPRETATION

Gender_num		N	Minimum	Maximum	Mean	Std. Deviation
M	POSTIVE	9	12	26	19.67	4.743
	NEGATIVE	9	15	25	20.44	3.167
	GENERAL	9	30	51	41.78	6.960
	TOTAL	9	59	101	81.89	13.365
	Valid (listwise)	N 9				
F	POSTIVE	8	15	30	21.50	5.503
	NEGATIVE	8	16	28	21.63	4.033
	GENERAL	8	32	58	43.75	9.051
	TOTAL	8	63	116	86.88	18.404
	Valid (listwise)	N 8				

The descriptive statistics table presents the mean, standard deviation, minimum, and maximum scores of PANSS Positive, Negative, General, and Total scores according to gender. The total sample consisted of 17 patients, including 9 males and 8 females.

For **male patients**, the mean scores were: Positive ($M = 19.67$, $SD = 4.74$), Negative ($M = 20.44$, $SD = 3.17$), General ($M = 41.78$, $SD = 6.96$), and Total ($M = 81.89$, $SD = 13.36$).

For **female patients**, the mean scores were slightly higher: Positive ($M = 21.50$, $SD = 5.50$), Negative ($M = 21.63$, $SD = 4.03$), General ($M = 43.75$, $SD = 9.05$), and Total ($M = 86.88$, $SD = 18.40$).

Although females show marginally higher mean scores across all PANSS domains, the differences are small, and variability (standard deviation) is slightly greater among females, indicating more dispersion in symptom severity. Overall, both groups demonstrate comparable levels of symptom severity.

Gender_num			POSTIV E	NEGATI VE	GENERA L	TOTA L
M	N	Valid	9	9	9	9
		Missing	0	0	0	0
	Mean		19.67	20.44	41.78	81.89
	Median		20.00	20.00	42.00	81.00
	Mode		12 ^a	19	30 ^a	59 ^a
	Std. Deviation		4.743	3.167	6.960	13.365
F	N	Valid	8	8	8	8
		Missing	0	0	0	0
	Mean		21.50	21.63	43.75	86.88
	Median		20.50	21.50	44.00	86.00
	Mode		15 ^a	16 ^a	32 ^a	63 ^a
	Std. Deviation		5.503	4.033	9.051	18.404

The frequency tables display the distribution of individual PANSS scores within male and female groups. Each score's frequency, percentage, valid percentage, and cumulative percentage are presented.

Among males (n = 9), Positive scores ranged from 12 to 26, and Negative scores ranged from 15 to 25, with most values evenly distributed (each score contributing approximately 11.1%).

Among females (n = 8), Positive scores ranged from 15 to 30, and Negative scores ranged from 16 to 28, with each score contributing approximately 12.5%

The frequency distribution indicates that symptom scores are spread across mild to moderate ranges in both genders, without extreme clustering at very high severity levels. The relatively even distribution suggests balanced representation of symptom severity within the sample.

Correlations

Gender_num				TOTAL
Spearman's rho M	POSTIVE	Correlation		.950*
		Coefficient Sig. (2-tailed)		*
	N			.000
				9
F	NEGATIVE	Correlation		.594
		Coefficient		.092
	Sig. (2-tailed)			9
		N		
GENERAL	TOTAL	Correlation		1.000
		Coefficient Sig. (2-tailed)		**
	N			.
				9
F	POSTIVE	Correlation		.976*
		Coefficient Sig. (2-tailed)		*
	N			.000
				8
GENERAL	NEGATIVE	Correlation		.952*
		Coefficient		*
	Sig. (2-tailed)			.000
		N		8
TOTAL	GENERAL	Correlation		1.000
		Coefficient Sig. (2-tailed)		**
	N			.
				8
TOTAL	TOTAL	Correlation		1.000
		Coefficient Sig. (2-tailed)		.
	N			8

**. Correlation is significant at the 0.01 level (2-tailed).

In the male group, the relationship between specific symptoms and the overall severity (Total score) varies significantly:

- **General Psychopathology & Total:** You have a perfect correlation ($r_s = 1.000$). This suggests that in your male sample, the General domain is the primary driver of the Total score.
- **Positive Symptoms:** There is an extremely strong, significant positive correlation ($r_s = .950$, $p < .001$). As positive symptoms increase, the total score increases predictably.

- **Negative Symptoms:** This is the outlier. The correlation is moderate ($r_s = .594$) but **not statistically significant** ($p = .092$).
 - *Interpretation:* For the males in your study, negative symptoms (like social withdrawal or flat affect) do not track as closely with the overall PANSS total as the other domains do.

2. Summary for Females (F, N=8)

For the female group, the symptoms are much more "synchronized." Every single domain shows a near-perfect relationship with the Total score.

- **General Psychopathology & Total:** Again, a perfect correlation ($r_s = 1.000$).
- **Positive Symptoms:** Extremely strong and significant ($r_s = .976$, $p < .001$).
- **Negative Symptoms:** Unlike the males, the females show a very strong, significant correlation here ($r_s = .952$, $p < .001$).

MANN – WHITNEY TEST

Hypothesis Test Summary			
	Null Hypothesis	Test	Sig. Decision
1	The distribution of PANSS_POS is the same across categories of GENDER.	Independent-Samples Mann-Whitney U Test	.667 ¹ Retain the null hypothesis.
2	The distribution of PANSS_NEG is the same across categories of GENDER.	Independent-Samples Mann-Whitney U Test	.333 ¹ Retain the null hypothesis.
3	The distribution of PANSS_GEN is the same across categories of GENDER.	Independent-Samples Mann-Whitney U Test	1.000 ¹ Retain the null hypothesis.
4	The distribution of PANSS_TOTAL is the same across categories of GENDER.	Independent-Samples Mann-Whitney U Test	.667 ¹ Retain the null hypothesis.
5	The distribution of IMAGING_AVAILABILITY is the same across categories of GENDER.	Independent-Samples Mann-Whitney U Test	1.000 ¹ Retain the null hypothesis.
6	The distribution of IMAGING_RESULT is the same across categories of GENDER.	Independent-Samples Mann-Whitney U Test	1.000 ¹ Retain the null hypothesis.

Asymptotic significances are displayed. The significance level is .05.

¹Exact significance is displayed for this test

The Independent Samples Mann–Whitney U test was conducted to examine whether there were significant differences between male and female patients in terms of PANSS scores (Positive, Negative, General, and Total) and neuroimaging variables (Imaging Availability and Imaging Result).

The results indicated that all p-values were greater than the significance level of 0.05 (PANSS_POS = .667, PANSS_NEG = .333, PANSS_GEN = 1.000, PANSS_TOTAL = .667, IMAGING_AVAILABILITY = 1.000, IMAGING_RESULT = 1.000).

LIMITATIONS OF THE STUDY

1. The sample size was small, consisting of only 17 participants.

2. Neuroimaging data were based on clinical reports rather than detailed quantitative analysis.
3. The study employed a cross-sectional design, limiting the ability to examine changes over time.
4. Important variables such as duration of illness and medication effects were not extensively analyzed.
5. Data were collected from a single clinical setting, which may limit generalizability.

SUGGESTIONS FOR FUTURE RESEARCH

Future research should include larger and more diverse samples to improve generalizability. Longitudinal studies may help examine how neuroimaging findings evolve during the course of the illness. Advanced imaging techniques capable of measuring brain connectivity and structural changes in greater detail should also be incorporated.

Additionally, integrating neuroimaging with cognitive assessments, genetic studies, and psychological evaluations may provide a more comprehensive understanding of schizophrenia.

CONCLUSION

The present study explored the role of neuroimaging in understanding schizophrenia by examining the relationship between imaging findings and clinical symptom severity. The results indicated that both male and female patients exhibited comparable levels of symptom severity, and no significant gender differences were observed in PANSS scores or neuroimaging outcomes.

Although neuroimaging findings did not significantly differ across gender groups, the study highlights the importance of integrating neuroimaging data with standardized clinical assessments. Neuroimaging techniques provide valuable insights into the structural and functional abnormalities associated with schizophrenia and contribute to a deeper understanding of the disorder's neurobiological foundations.

Overall, the findings support the view that schizophrenia is a complex condition involving interactions between clinical symptoms and underlying brain mechanisms. Continued research integrating neuroimaging and clinical assessment may enhance diagnostic accuracy and inform more effective treatment strategies.

ACKNOWLEDGEMENT

I would like to express my sincere gratitude to my research guide Dr. Madhu Pandey, for her valuable guidance, constant encouragement and constructive suggestion through - out the course of this research work. Without her support and motivation this research would have not been possible.

I am also thankful to the Head of the Department, Dr. S. Z. H. Zaidi, Amity Institute of Behavioural and Allied Sciences, Amity University, Lucknow Campus, Uttar Pradesh, for their continuous support and cooperation during my academic journey.

I extend my heartfelt thanks to all the participants who willingly took part in the study and provided the necessary data for this research.

Akriti Singh

MA Clinical Psychology, 4th Semester, Batch 2024-2026

Amity University, Lucknow Campus

Uttar Pradesh.

REFERENCES

1. Andreasen, N. C., et al. (1998). Neurodevelopmental model of schizophrenia. *Biological Psychiatry*.
2. Dabiri, M., et al. (2022). Neuroimaging in schizophrenia: A review article. *Frontiers in Neuroscience*.
3. Howes, O. D., & Kapur, S. (2009). The dopamine hypothesis of schizophrenia. *Schizophrenia Bulletin*.
4. Howes, O. D., et al. (2023). Neuroimaging in schizophrenia and synaptic alterations. *Neuropsychopharmacology*.
5. Jameei, H., et al. (2024). Linking polygenic risk of schizophrenia with MRI brain measures. *Schizophrenia Bulletin*.
6. Johnstone, E. C., et al. (1976). Cerebral ventricular size and schizophrenia. *The Lancet*.
7. Li, Q., et al. (2024). Aberrant spontaneous brain activity in schizophrenia. *Progress in Neuro-Psychopharmacology*.
8. Minzenberg, M. J., et al. (2009). fMRI meta-analysis of executive function in schizophrenia. *American Journal of Psychiatry*.
9. Shenton, M. E., et al. (2001). MRI findings in schizophrenia. *Schizophrenia Research*.